Peg-IFN-α2a联合肝复乐胶囊对HbeAg阳性慢性乙型肝炎抗肝纤维化的疗效

Abstract
Figure/Table
References
Related Citation (10)

Download: PDF (754 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the anti-liver fibrosis effect of pegylated interferon α2a(Peg-IFN-α2a) combined with Ganfule capsules on patients with HbeAg postive chronic hepatitis B(CHB).Methods 108 patients with HbeAg postive CHB were divided into two groups. Patients in group A(n=56) were treated with Peg-IFN-α2a and Ganfule capsules, while patients in group B(n=52) were treated with Peg-IFN-α2a alone. The course of treatment of the two groups was 48 weeks. The liver function, HBV DNA level, serum marker of liver fibrosis and Fibroscan score over the 48 weeks were collected and analyzed. ELISA method was performed to measure the level of serum hyaluronic acid (HA), laminin (LN), procollagen Ⅲ N-terminal peptide (PⅢP), and type Ⅳ collagen (CⅣ).Results At the 48 th week, the level of HBV DNA (LOG10 copies/ml) was decreased from (6.78±1.36 )to (2.36±0.42 ) in group A and from( 6.54±1.25 )to( 2.43±0.37)in group B. The level of ALT was decreased from(106.62±36.74)U/L to (33.22±8.75)U/L group A and that from(113.57±40.29)U/L to(40.64±11.37)U/L group B. The level of HBV DNA and ALT in both groups was significantly decreased compared with the level at baseline (P<0.01). The level of serum HA, LN, PⅢP and CⅣ in both groups was also significantly decreased (P<0.01). Furthermore, the levels of serum HA, LN, PⅢP and CⅣ at the 48 th week were significantly lower in group A (P<0.05). The Fibroscan score of group A were decreased from(12.78±3.32)Kpa to(7.43±2.21)Kpa and that of group B from (13.34±3.35)kPa to(9.24±2.06)kPa. The Fibroscan scores in both groups were significantly decreased compared with the level at baseline (P<0.01).Also, Fibroscan scores at the 48th week were significant lower in group A than in group B(P<0.05).Conclusions The combination of Peg-IFN-α2a with Ganfule capsules can more effectively improve liver fibrosis of patients with HbeAg postive CHB.

Key words： pegylated interferon α2a Ganfule capsules chronic hepatitis B liver fibrosis

Received: 08 October 2016

ZTFLH:

R512.62

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jiwan
	ZHOU Jianli
	ZHANG Xiaofang
	LONG Li
	and WU Gang

Cite this article:

ZHANG Jiwan,ZHOU Jianli,ZHANG Xiaofang等. Anti-liver fibrosis effect of pegylated interferon α2b combined with Ganfule capsules on patients with HbeAg postive CHB,China[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(3): 257-260.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I3/257

[1]	Lok A S, Mc Mahon B J, Brown R S, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology, 2016,63(1):284-306.
[2]	Shin S K, Kim J H, Park H, et al. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment[J]. J Gastroenterol Hepatol, 2015,30(12):1775-1781.
[3]	梁志伟.苦参碱和肝复乐治疗肝纤维化后血清肝纤维化指标的变化[J].检验医学与临床,2013, 24(3): 283-285.
[4]	中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中华肝脏病杂志, 2015,23(12):888-905.
[5]	Calvaruso V, Craxi A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? [J]. Liver Int, 2014, 34(Suppl)1:85-90.
[6]	Su T H, Kao J H, Liu C J. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis[J]. Int J Mol Sci, 2014,15(6):10578-10604.
[7]	徐列明.中药抗肝纤维化的研究现状及前景[J].上海中医药大学学报, 2012,26(2):9-11.
[8]	Neuman M G, Cohen L B, Nanau R M. Hyaluronic acid as a non-invasive biomarker of liver fibrosis[J]. Clin Biochem, 2016, 49(3) :302-315.
[9]	赵红,吕蓓, 黄绍萍. Fibroscan联合血清肝纤维化标志物诊断早期肝硬化的研究[J].胃肠病学和肝脏病学杂志, 2014, 24(4):447-449.
[10]	杨素芳. 肝苏颗粒治疗慢性乙型肝炎肝纤维化115例[J]. 陕西中医, 2012, 33(7): 838-839.
[11]	Cassinotto C, Lapuyade B, Mouries A.Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R) [J]. J Hepatol, 2014, 61(3):550-557.
[12]	贺新春. 肝复乐胶囊加常规治疗乙型肝炎肝硬化效果观察[J].人民军医,2016,67(7):714-715.